<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The relentless decline in beta-cell function frequently observed in type 2 diabetic patients, despite optimal drug management, has variously been attributed to <z:chebi fb="105" ids="17234">glucose</z:chebi> toxicity and lipotoxicity </plain></SENT>
<SENT sid="1" pm="."><plain>The former theory posits <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>, an outcome of the disease, as a secondary force that further damages beta-cells </plain></SENT>
<SENT sid="2" pm="."><plain>The latter theory suggests that the often-associated defect of <z:hpo ids='HP_0003077'>hyperlipidemia</z:hpo> is a primary cause of <z:hpo ids='HP_0006279'>beta-cell dysfunction</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>We review evidence that patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> continually undergo <z:mp ids='MP_0003674'>oxidative stress</z:mp>, that elevated <z:chebi fb="105" ids="17234">glucose</z:chebi> concentrations increase levels of reactive oxygen species in beta-cells, that islets have intrinsically low <z:chebi fb="11" ids="22586">antioxidant</z:chebi> enzyme defenses, that <z:chebi fb="11" ids="22586">antioxidant</z:chebi> drugs and overexpression of <z:chebi fb="11" ids="22586">antioxidant</z:chebi> enzymes protect beta-cells from <z:chebi fb="105" ids="17234">glucose</z:chebi> toxicity, and that lipotoxicity, to the extent it can be attributable to <z:hpo ids='HP_0003077'>hyperlipidemia</z:hpo>, occurs only in the context of preexisting <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>, whereas <z:chebi fb="105" ids="17234">glucose</z:chebi> toxicity can occur in the absence of <z:hpo ids='HP_0003077'>hyperlipidemia</z:hpo> </plain></SENT>
</text></document>